2 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Contrave: new trials by email Literature Review of Contrave trials Research Report on Contrave
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide - Obesity | Phase 4 | Active not recruiting | The Cleveland Clinic | 150 | 2025-03-01 | 2026-09-30 |
| Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity Contrave, Placebo, Diet Program - Obesity, Weight Loss | Phase 4 | Recruiting | The Royal's Institute of Mental Health Research | 40 | 2024-07-04 | 2025-07-24 |
| Weight Loss Study: Genetics and Response to Naltrexone/Bupropion Naltrexone-Bupropion Combination - Obesity | Phase 4 | Recruiting | Columbia University | 120 | 2023-06-08 | 2026-06-10 |
| Use of Mysimba in Patients With Weight Regain After Bariatric Surgery Naltrexone-Bupropion Combination - Obesity, Morbid, Bariatric Surgery Candidate | Phase 4 | Unknown | Zuyderland Medisch Centrum | 116 | 2023-03-21 | 2023-05-30 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic Intervention Control, Counselling, Contrave - Obesity | Phase 4 | Completed | University of Nebraska | 86 | 2017-07-01 | 2024-08-29 |
| Naltrexone/Bupropion Cardiovascular Outcomes Study Naltrexone HCl/Bupropion HCl ER, Placebo - Obesity, Cardiovascular Diseases | Phase 4 | Terminated | Orexigen Therapeutics, Inc | 67 | 2016-01-01 | 2017-02-27 |
Obesity (6) · Weight Loss (2) · Cardiovascular Diseases (1) · Depression (1) · Medication Adherence (1) · Obesity, Morbid (1)
Columbia University (1) · Novo Nordisk A/S (1) · Orexigen Therapeutics, Inc (1) · The Cleveland Clinic (1) · The Royal's Institute of Mental Health Research (1) · University of Nebraska (1) · Zuyderland Medisch Centrum (1)
United States (5) · Canada (1) · Netherlands (1)
Bartolome Burguera, M.D (1) · Jan Willem Greve, MD, PhD, professor (1) · Judith Korner, MD,PhD (1) · Pierre Blier, M.D., Ph.D (1) · Trina M Aguirre (1)
R01DK132527 (1)